Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma

Serafeim-Chrysovalantis Kotoulas; Ioanna Tsiouprou; Kalliopi Domvri; Polyxeni Ntontsi; Athanasia Pataka; Konstantinos Porpodis

doi:10.3390/arm91040023

Advances in Respiratory Medicine (Jul 2023)

Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma

Serafeim-Chrysovalantis Kotoulas,
Ioanna Tsiouprou,
Kalliopi Domvri,
Polyxeni Ntontsi,
Athanasia Pataka,
Konstantinos Porpodis

Affiliations

Serafeim-Chrysovalantis Kotoulas: ICU, General Hospital of Thessaloniki “Hippokration”, 49th Kostantinoupoleos Street, 57642 Thessaloniki, Greece
Ioanna Tsiouprou: Pulmonary Clinic of Aristotle University of Thessaloniki, General Hospital of Thessaloniki “Georgios Papanikolaou”, Leoforos Papanikolaou, Exohi, 57010 Thessaloniki, Greece
Kalliopi Domvri: Laboratory of Histology-Embryology, Medical School, Aristotle University of Thessaloniki, Leoforos Agiou Dimitriou, 54124 Thessaloniki, Greece
Polyxeni Ntontsi: 2nd University Department of Respiratory Medicine, Attikon Hospital, 1st Rimini Street, Haidari,12462 Athens, Greece
Athanasia Pataka: Respiratory Failure Clinic of Aristotle University of Thessaloniki, General Hospital of Thessaloniki “Georgios Papanikolaou”, Leoforos Papanikolaou, Exohi, 57010 Thessaloniki, Greece
Konstantinos Porpodis: Pulmonary Clinic of Aristotle University of Thessaloniki, General Hospital of Thessaloniki “Georgios Papanikolaou”, Leoforos Papanikolaou, Exohi, 57010 Thessaloniki, Greece

DOI: https://doi.org/10.3390/arm91040023
Journal volume & issue: Vol. 91, no. 4
pp. 288 – 300

Abstract

Read online

Long-acting muscarinic antagonists (LAMAs) are a class of inhalers that has recently been included as add-on therapy in the GINA guidelines, either in a single inhaler device with inhaled corticosteroids plus long-acting β2-agonists (ICS + LABA) (closed triple inhaler therapy) or in a separate one (open triple inhaler therapy). This review summarizes the existing evidence on the addition of LAMAs in patients with persistently uncontrolled asthma despite ICS + LABA treatment based on clinical efficacy in the reduction of asthma symptoms and exacerbations, the improvement in lung function, and its safety profile.

Published in Advances in Respiratory Medicine

ISSN: 2451-4934 (Print); 2543-6031 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system; Medicine: Medicine (General)
Website: https://www.mdpi.com/journal/arm

About the journal

Abstract

Keywords